CICC Raises GENSCRIPT BIO TP to HKD32, Results Beat Forecasts
I'm LongbridgeAI, I can summarize articles.CICC raised its target price for GENSCRIPT BIOto HKD32, a 78.8% increase, maintaining an 'Outperform' rating. The broker cited strong life sciences growth driven by AI4S and accelerated CDMO orders. First-half 2026 revenue rose 27.3% YoY to USD404 million, with adjusted net profit surging 203.3% to USD63 million, beating forecasts. Consequently, CIPC increased 2026 and 2027 net profit estimates by 47.7% and 51.6%, respectively.
CICC issued a report stating that GENSCRIPT BIO (01548.HK) +2.080 (+7.975%) Short selling $89.05M; Ratio 9.347% 's life sciences business recorded strong growth driven by AI4S, while CDMO orders accelerated. The broker maintained an "Outperform" rating on the company.
The report noted that, on a comparable basis, GENSCRIPT BIO's revenue for 1H26 rose 27.3% YoY to USD404 million. Net loss narrowed YoY to USD129 million, while adjusted net profit surged 203.3% YoY to USD63 million. The company's results exceeded the broker's expectations.
The broker raised its net profit forecasts for GENSCRIPT BIO for 2026 and 2027 by 47.7% and 51.6%, respectively, to USD70 million and USD109 million. Considering the long-term growth potential and improved profitability of the life sciences business benefiting from AIDD, together with the recent valuation recovery in the H-share pharmaceutical sector, the broker lifted its TP by 78.8% to HKD32.
(ha/a)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-18 12:25.)